City Center Advisors LLC acquired a new stake in Caris Life Sciences, Inc. (NASDAQ: CAI) during the

S&P 500 and Nasdaq 100 hit records as the 10-year yield retreats from a 24-year high; Constellat

Caris stock is pulling back after more than doubling in just two months. Wait for the IPO stock to o

Caris Life Sciences has an already established profiling business that provides revenue and cash flo

Caris Life Sciences, Inc. (CAI) was a big mover last session on higher-than-average trading volume.

The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi p

New partnership highlights the importance of finding cancer earlier through Caris Detect, a multi-ca

Seven studies will be presented, including two mini oral presentations and a poster tour presentatio

Caris Life Sciences (Nasdaq:CAI), the Nasdaq-listed Techbio company, has published a study describin

The study demonstrates the performance of Caris AI Insights™ to predict first-line treatment benefit

Caris AI Insights for pancreatic cancer is proprietary, only available to Caris Life Sciences custom

Nasdaq 100 falls 0.6% as traders wait on Nvidia and hot July PCE revives September rate-hike bets. E

Long-end Treasury yields snapped back toward 20-month highs; Walmart posted its worst session in fou

Dow Jones down 300 points, Deere & Co shares up 7.9% after beating earnings expectations. SCTX,

Caris Life Sciences delivered another strong quarter, raising full-year guidance and expanding margi

Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperfo

Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript

Caris Life Sciences,?Inc. (CAI) reported break-even quarterly earnings per share versus the Zacks Co

Caris Life Sciences NASDAQ: CAI reported record clinical volume and raised its full-year revenue out

Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday&

Caris Life Sciences (NASDAQ:CAI) raises FY2026 sales outlook from $1.000 billion-$1.020 billion to $

Revenue growth of 45% driven by strong performance in molecular profiling services, including approx

Caris Life Sciences is rated a 'Buy' at ~$16.5, with a blended fair value estimate of $22.3, implyin

IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio c

This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway m

IRVING, Texas, July 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-c

Ultra-deep Whole Genome and Whole Transcriptome sequencing combined with sophisticated AI algorithms

ALLENTOWN, Pa., June 24, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, was awarded a statewi

ALLENTOWN, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, today announced it ha

Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and

IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-c

Caris Life Sciences® (Nasdaq: CAI) ("Caris" or the "Company"), a leading next-genera

A selloff in high-flying chipmakers split Wall Street on Thursday, with Broadcom Inc. (NASDAQ:AVGO)‘

Stanley Druckenmiller cut Amazon, exited Alphabet while increasing bets on Argentina, commodities, s

Molecular profiling reports from most labs are static, reflecting clinical knowledge only at the tim

Citigroup analyst Patrick Donnelly maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowe

Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric next-generation AI TechBio company and

JP Morgan analyst Casey Woodring maintains Caris Life Sciences (NASDAQ:CAI) with a Overweight and

BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowers the pr

Caris Life Sciences (NASDAQ:CAI) affirms FY2026 sales outlook from $1.000 billion-$1.020 billion to

Caris Life Sciences (NASDAQ:CAI) reported quarterly sales of $216.174 million which beat the analyst

Caris Life Sciences® (NASDAQ:CAI), a leading, patient‑centric, next‑generation AI TechBio company an

Comprehensive molecular profiling paired with biomarker-driven trial matching provides cancer patien

U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro

Jefferies analyst Tycho Peterson initiates coverage on Caris Life Sciences (NASDAQ:CAI) with a Bu

Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperfo

Ultra-deep Whole Genome and Transcriptome Sequencing provides a more complete workup for myeloid mal

Caris Life Sciences stock surges on positive Achieve 1 cancer test data. See key CAI levels and stud

Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company an